Law firms Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business · 6 October 2016 · 1 min read Corporate and M&A Deal watch Linklaters Pinsent Masons Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryStarling launches new panel as 16 firms make the cutIn-HouseTheresa Hargreaves29 May 2026Pinsents self-refers to SRA over AI hallucination failingsLaw firmsWill Lewallen26 May 2026Linklaters and Hogan Lovells sweeten the deal on £2.7bn Tate & Lyle takeover bidLaw firmsKate Peacock18 May 2026‘It’s harder than it looks’ – inside the $1.65bn elite Indian cricket sale with the Macfarlanes partners behind the dealLaw firmsTom Cox29 May 2026‘We want to be there for the issues that keep our clients up at night’ – De Brauw co-head talks strategyLaw firmsTom Cox29 May 2026Latham hires three-partner City corporate team from Morrison FoersterLaw firmsWill Lewallen28 May 2026Dealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealLaw firmsAlex Ryan15 Jan 2024Dealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanLaw firmsAlex Ryan8 Dec 2023Deal Watch: activity powers on as Latham and A&O lead on $19bn energy joint ventureLaw firmsMegan Mayers9 Sep 2022